4//SEC Filing
Lang Matthew 4
Accession 0001209191-24-003276
CIK 0001806952other
Filed
Feb 12, 7:00 PM ET
Accepted
Feb 13, 8:25 PM ET
Size
7.4 KB
Accession
0001209191-24-003276
Insider Transaction Report
Form 4
Lang Matthew
Chief Business Officer
Transactions
- Award
Common Stock
2024-02-09+50,000→ 50,000 total - Award
Option (right to buy)
2024-02-09+500,000→ 500,000 totalExercise: $1.80Exp: 2034-02-08→ Common Stock (500,000 underlying)
Footnotes (2)
- [F1]The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months.
Documents
Issuer
Lyell Immunopharma, Inc.
CIK 0001806952
Entity typeother
Related Parties
1- filerCIK 0001712069
Filing Metadata
- Form type
- 4
- Filed
- Feb 12, 7:00 PM ET
- Accepted
- Feb 13, 8:25 PM ET
- Size
- 7.4 KB